Effects of Termination of the Agreement. Upon any termination of this Agreement, the following shall apply (in addition to any other rights and obligations under Section 13.8 or otherwise under this Agreement with respect to such termination):
Effects of Termination of the Agreement. Upon termination of this Agreement with respect to one or more Regions or in its entirety (the “Terminated Regions”; with the entire Territory being the Terminated Regions in the event of termination of this Agreement in its entirety), the following shall apply with respect to the Terminated Regions (in addition to any other rights and obligations under this Article 14 or otherwise under this Agreement with respect to such termination):
Effects of Termination of the Agreement. Upon any early termination of this Agreement (other than, for avoidance of doubt, by operation of Section 14.1), in its entirety or on a country-by-country basis:
Effects of Termination of the Agreement. Upon termination or suspension of the CLINICAL TRIAL, the Party not being in breach of its contractual obligations shall be entitled to rescind the Agreement. The Parties shall ensure the participants’ safety upon termination of the CLINICAL TRIAL for whatever reason, guaranteeing also the continuity of the treatment administered and compliance with the current laws governing the subject matter.
Effects of Termination of the Agreement. Upon any termination of this Agreement, in its entirety or on a country-by-country or Licensed Product-by-Licensed Product basis (other than termination by Lumena under Section 8.2):
Effects of Termination of the Agreement with Respect to the Licensed Field. Upon termination of this Agreement by BMS under Section 13.2(a) or 13.10 or by Alder under Section 13.3(a)(i), 13(a)(iii) or 13.4(a), the following shall apply with respect to the terminated Region(s) (in addition to any other rights and obligations under Section 13.2, 13.3, 13.4 and Section 13.8 or otherwise under this Agreement with respect to such termination):
Effects of Termination of the Agreement with Respect to the Cancer Field. Upon termination of this Agreement by BMS under Section 13.2(b) or 13.10 or by Alder under Section 13.3(a)(ii) or 13.3(a)(iii) or 13.4(b), the following shall apply with respect to the terminated Region(s) (in addition to any other rights and obligations under Section 13.2, 13.3, 13.4 and Section 13.8 or otherwise under this Agreement with respect to such termination):
Effects of Termination of the Agreement. Upon any early termination of this Agreement, in its entirety or on a country-by-country or EU basis:
Effects of Termination of the Agreement. (a) Upon termination of this Agreement, all rights and obligations of the Parties shall cease immediately, unless otherwise indicated in this Agreement; provided, however, that if this Agreement has been terminated by Eidos pursuant to Section 13.3(a), any Sublicensee will, as of the effective date of termination of this Agreement, automatically and without any additional consideration become a direct licensee of Eidos with respect to the rights sublicensed to the Sublicensee by Bayer under this Agreement, so long as (i) such Sublicensee is not in breach of its sublicense agreement with Bayer, (ii) such Sublicensee agrees in writing to comply with all of the terms of this Agreement to the extent applicable to the rights originally sublicensed to it by Bayer, and (iii) such Sublicensee agrees to pay directly to Eidos such Sublicensee’s payments under this Agreement to the extent applicable to the rights sublicensed to it by Bayer. The foregoing shall not apply if a Sublicensee provides written notice to Eidos that it does not wish to receive and retain the rights afforded to it pursuant to this Section 13.4(a). At Bayer’s request, and its sole cost and expense, Eidos will enter into a standby license with any Sublicensee confirming the benefits conferred to such Sublicensee by this Section 13.4(a).
Effects of Termination of the Agreement. Upon termination of this Agreement by TB Alliance under Sections 8.3 or 8.4, by either Party under Sections 8.5 or 8.6, Company shall assist TB Alliance in ensuring that TB Alliance has the freedom and ability to carry out Project activities either directly itself and/or through Third Parties, and without limiting the foregoing, or being limited thereby: (i) it is acknowledged by the Company that a material failure by Company to timely complete the transfers contemplated by Section 4.3(b) will, in addition to any other right or remedy available to TB Alliance at law or in equity, give rise to a right by TB Alliance to seek reimbursement from Company of all amounts paid by TB Alliance to the Company under Article 3; and (ii) in such event Company shall promptly pay to TB Alliance the full amount of any and all such reimbursement amounts claimed by TB Alliance. Termination or expiration of this Agreement shall not affect rights or obligations of the Parties under this Agreement that have accrued prior to the date of termination or expiration of this Agreement. Notwithstanding anything to the contrary, the following provisions shall survive and apply after expiration or termination of this Agreement: Sections 2.1,2.2, 2.4, 3.1,3.3, 8.8, and Articles 1, 4, 5, 6, 7 and 9.
